


Evolution Briefing: Novavax Announce New SVP Global Sales

Novavax, a late-stage biotechnology company developing next-generation vaccines, announced the appointment of **Frank Czworka** as Senior Vice President (Global Sales), a role that brings responsibility for leading sales planning and distribution.



Mr. Czworka brings more than two decades of biopharmaceutical experience to Novavax, most recently serving as Vice President of Global Customer Engagement at U.S. Pharmacopeia. In sales and marketing leadership positions at Osiris Therapeutics, Auxilium Pharmaceuticals, MedImmune and TAP Pharmaceuticals, Mr. Czworka has assembled, developed, deployed and directed award-winning global sales and marketing teams to achieve business objectives. He has launched multiple medications across a variety of therapeutic areas while increasing patient access to vital treatments.



Novavax's Strategy

Novavax, like many biotech companies, are pursuing a COVID-19 vaccine. There is strong growth potential for Novavax; its stock valuation jumped from \$4 at the start of 2020 to \$47 today. Novavax is currently valued at \$3 billion, however, with competitors in the vaccine industry such as Moderna (valued at \$24 billion) and Sanofi (valued at \$127 billion), they are comparatively small, despite being one of the stronger companies in the vaccine race. In multiple

About Novavax

Novavax, is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

Source: Novavax

clinical trials, their Flu vaccine has been proven to be superior to Sanofi's (who are considered to be a market leader) - with FDA submission scheduled for later this year. CEPI was so impressed with Novavax's technology that they invested \$388 M in the company's platform to help fund its COVID-19 research. Novavax, which is already well-positioned to emerge as a market leader in flu vaccines, also has a strong chance to succeed with its COVID-19 vaccine.



Frank Czworka

Stanley Erck, President & CEO of Novavax: "Frank's extensive commercial and sales expertise will be invaluable to Novavax's transformation into a commercial stage organization, I am confident that the company will benefit greatly from his expertise as we advance our efforts to bring NVX CoV2373 and NanoFlu to market."

Frank Czworka, SVP Global Sales of Novavax: "This is an exciting time to join Novavax, with much to be accomplished as we advance our COVID-19 candidate and prepare the regulatory submission for NanoFlu," said Mr. Czworka. "I'm excited to contribute to the team so that we can positively impact the lives of patients and reduce the global burden of these infectious diseases."market."